Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Trends Cancer. 2020 Jun;6(6):443-444. doi: 10.1016/j.trecan.2020.02.018. Epub 2020 Mar 13.
Programmed death 1 (PD1) has emerged as a major inhibitor of antitumor T cells, and anti-PD1 therapies have demonstrated clinical efficacy in multiple cancers. However, the impact of PD1 on other immune cells had remained unclear. A recent study by Strauss et al. describes how myeloid cell-intrinsic PD1 signaling limits myelopoiesis in cancer pertinent to anti-PD1 therapies.
程序性死亡受体 1（PD1）已成为抗肿瘤 T 细胞的主要抑制剂，抗 PD1 疗法在多种癌症中已显示出临床疗效。然而，PD1 对其他免疫细胞的影响仍不清楚。Strauss 等人的最近一项研究描述了 PD1 信号如何在肿瘤中限制髓系细胞的内在造血作用，与抗 PD1 疗法有关。
